Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 24.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offic |
| 10.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offic |
Stammdaten
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Unternehmen & Branche
| Name | Compass Therapeutics, Inc. |
|---|---|
| Ticker | CMPX |
| CIK | 0001738021 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 251,0 Mio. USD |
| Beta | 1,30 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -66,489,000 | 219,588,000 | 196,791,000 | ||
| 2025-09-30 | 10-Q | -14,259,000 | 231,259,000 | 209,613,000 | ||
| 2025-06-30 | 10-Q | -19,881,000 | 116,698,000 | 93,207,000 | ||
| 2025-03-31 | 10-Q | -16,633,000 | 131,451,000 | 110,279,000 | ||
| 2024-12-31 | 10-K | -49,375,000 | 140,403,000 | 125,233,000 | ||
| 2024-09-30 | 10-Q | -10,481,000 | 149,151,000 | 138,398,000 | ||
| 2024-06-30 | 10-Q | -13,076,000 | 155,611,000 | 146,104,000 | ||
| 2024-03-31 | 10-Q | -10,787,000 | 161,142,000 | 157,060,000 | ||
| 2023-12-31 | 10-K | -42,494,000 | 156,875,000 | 148,538,000 | ||
| 2023-09-30 | 10-Q | -9,964,000 | 170,038,000 | 160,045,000 | ||
| 2023-06-30 | 10-Q | -11,278,000 | 179,181,000 | 168,286,000 | ||
| 2023-03-31 | 10-Q | -7,837,000 | 187,975,000 | 175,265,000 | ||
| 2022-12-31 | 10-K | -39,225,000 | 199,645,000 | 181,638,000 | ||
| 2022-09-30 | 10-Q | -11,975,000 | 127,838,000 | 116,116,000 | ||
| 2022-06-30 | 10-Q | -8,494,000 | 140,256,000 | 126,928,000 | ||
| 2022-03-31 | 10-Q | -7,162,000 | 146,564,000 | 134,490,000 | ||
| 2021-12-31 | 10-K | -82,181,000 | 153,757,000 | 140,078,000 | ||
| 2021-09-30 | 10-Q | -5,975,000 | 34,899,000 | 23,888,000 | ||
| 2021-06-30 | 10-Q | -55,804,000 | 40,872,000 | 28,875,000 | ||
| 2021-06-20 | 10-Q | -63,223,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.